Granted Patent
B2
US 12,239,623 · App. 18/665,149 · Granted Mar 4, 2025
Sleep-improving compositions and methods of use
Assignee:
Bonafide Health, LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are compositions comprising two or more sleep-inducing agonists and/or a sleep-inducing antagonist. The compositions are for promoting healthy sleep quality and treating, ameliorating, preventing, or reducing one or more symptoms associated with menopause. Also described herein are methods utilizing the aforementioned compositions.
Claims (18)
1. A composition for promoting healthy sleep quality comprising two or more sleep-inducing agonists, wherein a first sleep-inducing agonist is L-theanine and a second sleep-inducing agonist is a magnesium salt, wherein L-theanine and the magnesium salt are present in a synergistic ratio of about 2:1 by weight.
2. The composition of claim 1 further comprises a sleep- inducing antagonist, wherein the sleep-inducing antagonist is S-adenosyl L-methionine (SAMe).
3. The composition of claim 1 , wherein the magnesium salt is magnesium glycinate.
4. The composition of claim 1 further comprises a third sleep-inducing agonist, wherein the third sleep-inducing agonist is gamma-aminobutyric acid (GABA).
5. The composition of claim 4 further comprises a brain- health supporting agent, wherein the brain-health supporting agent is phosphatidylserine.
6. The composition of claim 4 , wherein the composition further comprises a combination of a sleep-inducing antagonist and a gallic acid ester, wherein the sleep-inducing antagonist is S-adenosyl L-methionine (SAMe).
7. The composition of claim 6 , wherein the gallic acid ester is propyl gallate.
8. The composition of claim 7 further comprises a brain-health supporting agent, wherein the brain-health supporting agent is phosphatidylserine.
9. The composition of claim 1 further comprises a combination of a sleep-inducing antagonist and a gallic acid ester, wherein the sleep-inducing antagonist is S-adenosyl L-methionine (SAMe).
10. The composition of claim 9 , wherein the gallic acid ester is propyl gallate.
11. The composition of claim 10 further comprises a brain-health supporting agent, wherein the brain-health supporting agent is phosphatidylserine.
12. The composition of claim 2 , wherein wherein the composition further comprises propyl gallate.
13. The composition of claim 4 , wherein the amount of the magnesium salt, the amount of L-theanine, and the amount of GABA are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:3 of the magnesium salt to L-theanine to GABA by weight, respectively.
14. The composition of claim 5 , wherein the amount of the magnesium salt, the amount of L-theanine, the amount of GABA, and the amount of phosphatidylserine are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:3:1 of the magnesium salt to L-theanine to GABA to phosphatidylserine by weight, respectively.
15. The composition of claim 7 , wherein the amount of the magnesium salt, the amount of L-theanine, the amount of GABA, and the combined amount of SAMe and propyl gallate are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:3:4.12 of the magnesium salt to L-theanine to GABA to the combination of SAMe and propyl gallate by weight, respectively.
16. The composition of claim 8 , wherein the amount of the magnesium salt, the amount of L-theanine, the amount of GABA, the combined amount of SAMe and propyl gallate, and the amount of phosphatidylserine are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:3:4.125:1 of the magnesium salt to L-theanine to GABA to the combination of SAMe and propyl gallate to phosphatidylserine, respectively.
17. The composition of claim 10 , wherein the amount of the magnesium salt, the amount of L-theanine, and the combined amount of SAMe and propyl gallate are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:4.125 of the magnesium salt to L-theanine to the combination of SAMe and propyl gallate by weight, respectively.
18. The composition of claim 11 , wherein the amount of the magnesium salt, the amount of L-theanine, the combined amount of SAMe and propyl gallate, and the amount of phosphatidylserine are present in a synergistic ratio, wherein the synergistic ratio is about 1:2:4.125:1 of the magnesium salt to L-theanine to the combination of SAMe and propyl gallate to phosphatidyl serine by weight, respectively.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 16, 2024
From: KOMOROWSKI, JAMES R.; BERNSLEY, DEVON
To: JDS THERAPEUTICS, LLC
Reel/Frame 067430/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 16, 2024
From: JDS THERAPEUTICS, LLC
To: BONAFIDE HEALTH, LLC
Reel/Frame 067430/0792 →
Continuity (2)
Provisional Application
63466498
· May 15, 2023
References Cited (297)
US 3893999A
· Fiecchi
· 1975
[cited by applicant]
US 3954726A
· Fiecchi
· 1976
[cited by applicant]
US 4057686A
· Fiecchi
· 1977
[cited by applicant]
US 4389393A
· Schor et al.
· 1983
[cited by applicant]
US 4525345A
· Dunn et al.
· 1985
[cited by applicant]
US 4537772A
· Alexander et al.
· 1985
[cited by applicant]
US 4556678A
· Hsiao
· 1985
[cited by applicant]
US 4601894A
· Hanna et al.
· 1986
[cited by applicant]
US 4680323A
· Lowey
· 1987
[cited by applicant]
US 4687757A
· Parrott et al.
· 1987
[cited by applicant]
US 4692337A
· Ukigawa et al.
· 1987
[cited by applicant]
US 4695591A
· Hanna et al.
· 1987
[cited by applicant]
US 4756911A
· Drost et al.
· 1988
[cited by applicant]
US 4956173A
· Le Fur et al.
· 1990
[cited by applicant]
US 4968509A
· Radebaugh et al.
· 1990
[cited by applicant]
US 5073380A
· Babu et al.
· 1991
[cited by applicant]
US 5128249A
· Gennari
· 1992
[cited by applicant]
US 5137712A
· Kask et al.
· 1992
[cited by applicant]
US 5169642A
· Brinker et al.
· 1992
[cited by applicant]
US 5264446A
· Hegasy et al.
· 1993
[cited by applicant]
US 5439687A
· Compassi
· 1995
[cited by applicant]
US 5462747A
· Radebaugh et al.
· 1995
[cited by applicant]
US 5543154A
· Rork et al.
· 1996
[cited by applicant]
US 5753213A
· Moratti
· 1998
[cited by applicant]
US 5877935A
· Sato et al.
· 1999
[cited by applicant]
US 5922341A
· Smith et al.
· 1999
[cited by applicant]
US 5962522A
· Wacher et al.
· 1999
[cited by applicant]
US 6004575A
· Luessen et al.
· 1999
[cited by applicant]
US 6093703A
· La Greca
· 2000
[cited by applicant]
US 6180666B1
· Wacher et al.
· 2001
[cited by applicant]
US 6365185B1
· Ritschel et al.
· 2002
[cited by applicant]
US 6548555B1
· Curatolo
· 2003
[cited by applicant]
US 6555124B1
· Kolter
· 2003
[cited by applicant]
US 6596701B1
· Schwartz et al.
· 2003
[cited by applicant]
US 6635615B1
· Hebert
· 2003
[cited by applicant]
US 6759395B2
· Rao et al.
· 2004
[cited by applicant]
US 6943155B2
· Lichtenberger et al.
· 2005
[cited by applicant]
US 7303762B2
· New
· 2007
[cited by applicant]
US 7651995B2
· New
· 2010
[cited by applicant]
US 8314058B2
· New
· 2012
[cited by applicant]
US 8329208B2
· Harrison et al.
· 2012
[cited by applicant]
US 8580296B2
· Harrison et al.
· 2013
[cited by applicant]
US 8865203B2
· Harrison et al.
· 2014
[cited by applicant]
US 8975238B2
· Guan et al.
· 2015
[cited by applicant]
US 9801896B2
· Guan et al.
· 2017
[cited by applicant]
US 9925208B2
· Guan et al.
· 2018
[cited by applicant]
US 9931356B2
· Harrison et al.
· 2018
[cited by applicant]
US 20020106345A1
· Uhrich et al.
· 2002
[cited by applicant]
US 20020164369A1
· Rao et al.
· 2002
[cited by applicant]
US 20040028729A1
· Shojaei
· 2004
[cited by applicant]
US 20050129783A1
· McCleary
· 2005
[cited by examiner]
US 20050142187A1
· Treacy et al.
· 2005
[cited by applicant]
US 20050158382A1
· Cruz et al.
· 2005
[cited by applicant]
US 20050181047A1
· Romero
· 2005
[cited by applicant]
US 20050191349A1
· Boehm et al.
· 2005
[cited by applicant]
US 20060094782A9
· Wong et al.
· 2006
[cited by applicant]
US 20060127506A1
· Hebert
· 2006
[cited by applicant]
US 20060130160A1
· Dumas et al.
· 2006
[cited by applicant]
US 20060280789A1
· Ueki et al.
· 2006
[cited by applicant]
US 20070196272A1
· Eddington
· 2007
[cited by applicant]
US 20070265211A1
· Rath et al.
· 2007
[cited by applicant]
US 20080206333A1
· Freedman
· 2008
[cited by applicant]
US 20080279931A1
· Morrow
· 2008
[cited by applicant]
US 20090088404A1
· Freedman et al.
· 2009
[cited by applicant]
US 20090110729A1
· Giovannone
· 2009
[cited by applicant]
US 20090197824A1
· Freedman et al.
· 2009
[cited by applicant]
US 20100056627A1
· Higuchi et al.
· 2010
[cited by applicant]
US 20110027342A1
· MacDonald et al.
· 2011
[cited by applicant]
US 20110064712A1
· Amato
· 2011
[cited by applicant]
US 20130004563A1
· Shah et al.
· 2013
[cited by applicant]
US 20130142847A1
· MacDonald et al.
· 2013
[cited by applicant]
US 20140370108A1
· Harrison et al.
· 2014
[cited by applicant]
US 20150087679A1
· Helmi et al.
· 2015
[cited by applicant]
US 20150367366A1
· Edwards et al.
· 2015
[cited by applicant]
US 20180000881A1
· Fritz
· 2018
[cited by examiner]
US 20190022119A1
· Guan et al.
· 2019
[cited by applicant]
US 20190038573A1
· Westphal et al.
· 2019
[cited by applicant]
US 20190060345A1
· Harrison et al.
· 2019
[cited by applicant]
US 20200246404A1
· Yucel et al.
· 2020
[cited by applicant]
US 20230054630A1
· Seidensticker
· 2023
[cited by examiner]
CA 2298245
· 2000
[cited by applicant]
CA 2364063
· 2000
[cited by applicant]
CA 2677053
· 2008
[cited by applicant]
CA 2769682
· 2010
[cited by applicant]
CA 2769490
· 2011
[cited by applicant]
CA 2769582
· 2011
[cited by applicant]
CN 101012336
· 2007
[cited by applicant]
CN 101677543
· 2010
[cited by applicant]
CN 102695514
· 2012
[cited by applicant]
CN 105232515
· 2016
[cited by applicant]
CN 105476982
· 2016
[cited by applicant]
CN 106714810
· 2017
[cited by applicant]
CN 108853085
· 2018
[cited by applicant]
CN 111265509
· 2020
[cited by applicant]
DE 19839443
· 2000
[cited by applicant]
DE 102005024614
· 2006
[cited by applicant]
EP 0136464
· 1985
[cited by applicant]
EP 1731596
· 2006
[cited by applicant]
EP 2149369
· 2010
[cited by applicant]
EP 2193787
· 2010
[cited by applicant]
EP 2464358
· 2015
[cited by applicant]
EP 2949331
· 2015
[cited by applicant]
EP 2512490
· 2016
[cited by applicant]
JP S6072815
· 1985
[cited by applicant]
JP H01193206
· 1989
[cited by applicant]
JP H05271067
· 1993
[cited by applicant]
JP 2001514234A
· 2001
[cited by applicant]
JP 2002504514A
· 2002
[cited by applicant]
JP 2002538173A
· 2002
[cited by applicant]
JP 2003155242
· 2003
[cited by applicant]
JP 2005320354
· 2005
[cited by applicant]
JP 2007508248
· 2007
[cited by applicant]
JP 2008163009
· 2008
[cited by applicant]
JP 2010518021
· 2010
[cited by applicant]
JP 2015214518A
· 2015
[cited by examiner]
JP 5877935
· 2016
[cited by applicant]
JP 2016074725
· 2016
[cited by applicant]
RU 2014837
· 1994
[cited by applicant]
RU 2018314
· 1994
[cited by applicant]
RU 2246939
· 2005
[cited by applicant]
WO WO9911290
· 1999
[cited by applicant]
WO WO9943336
· 1999
[cited by applicant]
WO WO0051643
· 2000
[cited by applicant]
WO WO0112155
· 2001
[cited by applicant]
WO WO0249637
· 2002
[cited by applicant]
WO WO02083136
· 2002
[cited by applicant]
WO WO02092112
· 2002
[cited by applicant]
WO WO2005034920
· 2005
[cited by applicant]
WO WO2006044202
· 2006
[cited by applicant]
WO WO2006079212
· 2006
[cited by applicant]
WO WO2006125483
· 2006
[cited by applicant]
WO WO2007095092
· 2007
[cited by applicant]
WO WO2007133981
· 2007
[cited by applicant]
WO WO2008006581
· 2008
[cited by applicant]
WO WO2008065502
· 2008
[cited by applicant]
WO WO2008095142
· 2008
[cited by applicant]
WO WO2010008619
· 2010
[cited by applicant]
WO WO2010009449
· 2010
[cited by applicant]
WO WO2010027014
· 2010
[cited by applicant]
WO WO2010063756
· 2010
[cited by applicant]
WO WO2011012989
· 2011
[cited by applicant]
WO WO2011012990
· 2011
[cited by applicant]
WO WO2012012902
· 2012
[cited by applicant]
WO WO2014059522
· 2014
[cited by applicant]
WO WO2015159155
· 2015
[cited by applicant]
WO WO2016204657
· 2016
[cited by applicant]
WO 2024238657A2
· 2024
[cited by applicant]
Abbasi B, Kimiagar M, Sadeghniiat K, Shirazi MM, Hedayati M, Rashidkhani B. The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial. J Res Med Sci 2012; 1…
[cited by examiner]
Suhyeon Kim, Kyungae Jo, Ki-Bae Hong, Sung Hee Han & Hyung Joo Suh (2019) GABA and I-theanine mixture decreases sleep latency and improves NREM sleep, Pharmaceutical Biology, 57:1, 64-72, DOI: 10.1080/13880209.2018.1557…
[cited by examiner]
Hartzler, Melody. “Which type of magnesium is best?” PharmToTable, Oct. 19, 2020, https://pharmtotable.life/2020/09/19/which-type-of-magnesium-is-best/ (Year: 2020).
[cited by examiner]
“New S-Adenosilmethionine Salts and the Process for their Preparation,” Research Disclosure, Mason Publication, Hampshire, GB, 1991; 332: pp. 927-933.
[cited by applicant]
Alexander, “Hypertension and the pathogenesis of atheroscierosis oxidative stress and the mediation of arterial inflammatory response: A new perspective,” Hypertension, 1995; 25: pp. 155-161.
[cited by applicant]
Anstee et al., “S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility,” Journal of Hepatology, 2012; 57: pp. 1097-1109.
[cited by applicant]
Authors Unknown, “Final report on the amended safety assessment of Propyl Gallate,” International Journal of Toxicology, 2007; 26(3): pp. 89-118.
[cited by applicant]
Baldrick, “Pharmaceutical Excipient Development: The Need for Preclinical Guidance,” Regul Toxicol Pharmacol, 2000; 32(2): pp. 210-218.
[cited by applicant]
Berryhill et al., “Effect of wearables on sleep in healthy individuals: a randomized crossover trial and validation study,” J Clin Neurol, 2020; 16(5): pp. 775-783.
[cited by applicant]
Billyard et al., “Dietary magnesium deficiency decreases plasma melatonin in rats,” Magnesium Research, 2006; 19(3): pp. 157-161.
[cited by applicant]
Bottiglieri et al., “Ademetionine (S-adenosylomethionine) neuropharmacology: implications for drug therapies in psychiatric and neurological disorders,” Exp Opin Invest Drugs, 1997; 6(4): pp. 417-426.
[cited by applicant]
Bottiglieri et al., “Folate, vitamin B12, and S-adenosylmethionine,” Psychiatr Clin North Am, 2013; 36(1): pp. 1-13.
[cited by applicant]
Bottiglieri et al., “Transmethylation in depression,” Alabama J Med Sci, 1988; 25(3): pp. 296-301.
[cited by applicant]
Bottiglieri, “S-adenosyl-L-methionine (same): From the bench to the bedside-molecular basis of a pleiotrophic molecule,” Am J Clin Nutr, 2002; 76(5): p. 1151S-1157S.
[cited by applicant]
Bourdet et al., “Saturable absorptive transport of the hydrophilic organic cation ranitidine in caco-2 cells: Role of pH-dependent organic cation uptake system and P-glycoprotein,” Pharm. Res., 2006; 23(6): pp. 1165-117…
[cited by applicant]
Brandt et al., “Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research,” Drugs in R&D, 2017; 17(4): pp. 493-507.
[cited by applicant]
Brown et al., “Novel Protective Mechanisms for S-Adenosyl-L-methionine against Acetaminophen Hepatotoxicity: Improvement of Key Antioxidant Enzymatic Function,” Toxicol Lett, 2012; 212(3): pp. 320-328.
[cited by applicant]
Byun et al., “Safety and Efficacy of Gamma-Aminobutyric Acid from Fermented Rice Germ in Patients with Insomnia Symptoms: A Randomized, Double-Blind Trial,” J Clin Neurol, 2018; 14(3): pp. 291-295.
[cited by applicant]
Caro et al., “Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine,” Biochemical Pharmacology, 2005; 69: pp. 1081-1093.
[cited by applicant]
Cavallaro et al., “S-adenosylmethionine prevents oxidative stress and modulates glutathione metabolism in TgCRND8 mice fed a B-vitamin deficient diet,” J Alzheimers Dis., 2010; 20(4): pp. 997-1002.
[cited by applicant]
Chen et al., “Treatment of Lesch-Nyhan disease with S-adenosylmethionine: experience with five young Malaysians, including a girl,” Brain Dev., 2014; 36(7): pp. 593-60.
[cited by applicant]
Cimino et al., “Age-related modification of dopaminergic and β-adrenergic receptor system: Restoration to normal activity by modifying membrane fluidity with s-adenosylmethionine,” Life Sciences, 1984; 34(21): pp. 2029-…
[cited by applicant]
Delgado et al., “Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults,” JAAOS: Global Research and Reviews, 2018; 2(3).
[cited by applicant]
Deli, “Potential use of tight junction modulators to reversibly open membranous; barriers and improve drug delivery,” Biochim Biophys Acta, 2009; 788(4): pp. 892-910.
[cited by applicant]
Di Padova, “S-Adenosylmethionine in the treatment of osteoarthritis,” The American Journal of Medicine, 1987; 83(5A): pp. 60-65.
[cited by applicant]
Di Rocco et al., “Brief Report: S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial,” Mov Disorders, 2000; 15(6): pp. 1225-1229.
[cited by applicant]
Dubey et al., “Potentiation of arsenic neurotoxicity by folate deprivation: protective role of S-adenosyl methionine,” Nutr Neurosci, 2007; 10(5-6): pp. 199-204.
[cited by applicant]
Duizer et al. “Absorption enhancement, structural changes in tight junctions and cytotoxicity caused by palmitoyl carnitine in Caco-2 and IEC-18 cells,” J Pharmacol Exp Ther., 1998; 287(1): pp. 395-402.
[cited by applicant]
Edinoff et al., “Benzodiazepines: Uses, Dangers, and Clinical Considerations,” Neurology international, 2021; 13(4), 594-607.
[cited by applicant]
El Khoudary et al., “The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN),” Menopause, 2019; 26(10), 1213-1227.
[cited by applicant]
Erland et al., “Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content,” J Clin Sleep Med, 2017; 13(2): pp. 275-281.
[cited by applicant]
EUDRAGIT L 100, [online] [retrieved on Aug. 25, 2012] <URL: http://eudragit.evonik.com/product/eudragit/en/products-services/eudragit-products/enteric-formulations/l-100/Pages/default.aspx>.
[cited by applicant]
EUDRAGIT S 100, [online] [retrieved on Aug. 25, 2012] <URL: http://eudragit.evonik.com/product/eudragit/en/products-services/eudragit-products/enteric-formulations/s100/Pages/default.aspx>.
[cited by applicant]
Feng et al., “Correlation of antimutagenic activity and suppression of CYP1A with the lipophilicity of alkyl gallates and other phenolic compounds,” Mutation Research, 2003; 537(1): pp. 101-108.
[cited by applicant]
Friedel, “S-Adenosyl-L-methionine—A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism,” Drugs, 1989;…
[cited by applicant]
Furujo et al., “S-adenosylmethionine treatment in methionine adenosyltransferase deficiency, a case report,” Mol Genet Metab., 2012; 105(3): pp. 516-518.
[cited by applicant]
Gentile et al., “Age-associated decline of hepatic handling of cholephilic anions in humans is reverted by S-adenosylmethionine (SAMe),” Scan. J.Clin Lab Investigation, 1990; 50(5): pp. 565-571.
[cited by applicant]
Giulidori et al., “Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers”, Eur. J. Clin. Pharmacol., 1984; 27: pp. 119-121.
[cited by applicant]
Gren et al., “Porous cellulose matrices containing lipophilic release modifiers—a potential oral extended-release system,” Intl. J. Pharmaceutics, 1999; 184: pp. 7-19.
[cited by applicant]
Gröber et al., “Magnesium in prevention and therapy,” Nutrients, 2015; 7(9): pp. 8199-8226.
[cited by applicant]
Gunja, “The clinical and forensic toxicology of Z-drugs,” J Med Toxicol., 2013; 9 (2): pp. 155-162.
[cited by applicant]
Hidese et al., “Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial,” Nutrients, 2019; 11(10): 2362.
[cited by applicant]
Hirshberg Foundation for Pancreatic Cancer Research, About the Foundation; Pancreatic Cancer; Research; Patients & Caregivers. 5 pages, downloaded on Aug. 19, 2016 from: http://pancreatic.org/pancreatic-cancer/about-the…
[cited by applicant]
Hochman et al., “Mechanisms of absorption enhancement and tight junction regulation,” Journal of Controlled Release, 1994; 29(3): pp. 253-267.
[cited by applicant]
Holquist and Fava. “FDA safety page: Delayed-release vs. extended-release Rxs.” Drug Topics Aug. 14, 2012 [retrieved online] http://license.icopyright.net/user/viewFreeUse.act?fuid=MTY1MDlyNjY%3D [online], 2 pages.
[cited by applicant]
Jacobsen, et al., “Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation,” Scand J Rheumatol, 1991; 20(4): pp. 294-302.
[cited by applicant]
Kadakia et al., “Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes,” Supportive Care Cancer, 2016; 24(3): pp. 1061-1069.
[cited by applicant]
Kaida et al., “Validation of the Karolinska sleepiness scale against performance and EEG variables,” Clinical Neurophysiology, 2006; 117(7): pp. 1574-1581.
[cited by applicant]
Kaye et al., “Metabolism of Exogenous S-Adenosyl-L-Methionine in Patients with Liver Disease,” Drugs, 1990; 40: pp. 124-128.
[cited by applicant]
Kim et al., “GABA and L-theanine mixture decreases sleep latency and improves NREM sleep,” Pharm Biol, 2019; 57(1): pp. 64-72.
[cited by applicant]
Krzystanek et al., “S-adenozylo L-metionina w schorzeniach OUN. S-adenosyl L-methionine in CNS diseases,” Psychiatria Polska, 2011; 45(6): pp. 923-931. (English abstract provided).
[cited by applicant]
Labiche et al., “Clinical trials for Cytoprotection in stroke,” NeuroRx: The Journal of the American Society for Experimental Neuro Therapeutics, 2004; 1(1): pp. 46-70.
[cited by applicant]
Laudanno et al., “La prostaglandina E 1 (misoprostol) y el SAMe en la prevencion de las gastritis hemorragicas inducida por aspirins, en el hombre. Estudio endoscopico, histologico e histoquimico,” Acta Gastroenterol La…
[cited by applicant]
Laudanno, “Cytoprotective effect of S-Adenosylmethionine compared with that of misoprostol against ethanol-, aspirin-, and stress-induced gastric damage,” The American Journal of Medicine, 1987; 83(Supp 5A): pp. 43-47.
[cited by applicant]
Lee et al., “Hypothesis: a unifying mechanism for nutrition and chemicals as lifelong modulators of DNA hypomethylation,” Environ Health Perspect, 2009; 117: pp. 1799-1802.
[cited by applicant]
Li et al., “Effects of S-adenosylmethionine and methylthioadenosine on inflammation-induced colon cancer in mice,” Carcinogenesis, 2012; 33(2): pp. 427-435.
[cited by applicant]
Linnebank et al., “s-Adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease,” Neurodegenerative Disease, 2010; 7: pp. 373-378.
[cited by applicant]
Loenen, S-Adenosylmethionine: jack of all trades and master of everything? Biomedical Society Transactions, 2006; 34(2): pp. 330-333.
[cited by applicant]
Lu and Mato, “S-Adenosylmethionine in cell growth, apoptosis and liver cancer,” Journal of Gastroenterology and Hepatology, 2008; 23 Supp:S73-77.
[cited by applicant]
Lu and Mato, “S-adenosylmethionine in liver health, injury, and cancer,” Physiol Rev, 2012; 92(4): pp. 1515-1542.
[cited by applicant]
Lu, Shelly, “S-Adenosylmethionine,” The International Journal of Biochemistry & Cell Biology, 2000; 32: pp. 391-395.
[cited by applicant]
Luo et al., “S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gasatric cancer and colon cancer,” Int. J. of Biological Sciences, 2010; 6(7): pp…
[cited by applicant]
Lyon et al., “The effects of L-theanine (Suntheanine®) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial,” Altern Med …
[cited by applicant]
Manna et al., “Age-related decline in S-adenosylmethionine and protein methyl esterification levels in bovine lenses,” Arch Gerontol Geriatr, 1992; Supp. 3: pp. 237-248.
[cited by applicant]
Material Safety Data Sheet of S-Adenosyl-L-methionine disulfate tosylate, United States Pharmacopeia [online], Dec. 27, 2011 http://www.usp.org/pdf/EN/referenceStandards/msds/1012134.pdf, [retrieved online Aug. 16, 2012…
[cited by applicant]
Mato et al., “S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial,” Journal of Hepatology, 1999; 30(6): pp. 1081-1089.
[cited by applicant]
Mato et al., “S-Adenosylmethionine synthesis: Molecular mechanisms and clinical implications,” Pharmacol. Ther., 1997; 73(3): pp. 265-280.
[cited by applicant]
McMillan et al., “S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytes,” Journal of Pharmacy and Pharmacology, 2005; 57: pp. 599-605.
[cited by applicant]
Najm et al., “S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial,” [ISRCTN36233495] BMC Musculoskeletal Disorders, 2004; 5: 15 pages.
[cited by applicant]
New Review Article of Pharmaceutics, Apr. 10, 1987, Third Edition, pp. 262-268.
[cited by applicant]
Ngo et al., “An Updated Review on Pharmaceutical Properties of Gamma-Aminobutyric Acid,” Molecules (Basel, Switzerland), 2019; 24(15).
[cited by applicant]
Nobre et al., “L-theanine, a natural constituent in tea, and its effect on mental state,” Asia Pac J Clin Nutr, 2008; 17(1): pp. 167-168.
[cited by applicant]
Oketch-Rabah et al., “United States Pharmacopeia (USP) Safety Review of Gamma-Aminobutyric Acid (GABA),” Nutrients, 2021; 13(8).
[cited by applicant]
Papakostas et al., “Folates and S-adenosylmethionine for major depressive disorder,” Can J Psychiatry, 2012; 57(7): pp. 406-413.
[cited by applicant]
Pascale et al., “Chemoprevention of hepatocarcinogenesis:S-adenosyl-L-methionine,” Alcohol, 2002; 27: pp. 193-198.
[cited by applicant]
Paterson et al., “A translational, caffeine induced model of onset insomnia in rats and healthy volunteers,” Psychopharmacology (Berl), 2007; 191: pp. 943-950.
[cited by applicant]
Poirier et al., “Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathy,” Metabolism, 2001; 50(9): pp. 1014-1018.
[cited by applicant]
Price et al., “Effect of butylated hydroxytoluene, curcumin, propyl gallate and thiabendazole on cytochrome P450 forms in cultured human hepatocytes,” Xenobiotica, 2008; 38(6): pp. 574-586.
[cited by applicant]
Proctor et al., “Mechanisms underlying saturable intestinal absorption of metformin,” Drug Metab. Dispos., 2008; 36(8): pp. 1650-1658.
[cited by applicant]
Remington et al., “A Phase II randomized clinical trial of a nutritional formulation for cognition and mood in Alzheimer's disease,” Journal of Alzheimer's Disease, 2015; 45: pp. 395-405.
[cited by applicant]
Sahelian, “SAM-e” Datasheet [online][retrieved on Aug. 15, 2011 from internet archive dated Jul. 3, 2004], <original URL:http://www.raysahelian.com/sam-e.html> <internet archive URL:http://web.archive.org/web/2004070306…
[cited by applicant]
Sahin et al., “Inhibition of angiogenesis by S-adenosylmethionine,” Biochemical and Biophysical Research Communication, 2011; 408: pp. 145-148.
[cited by applicant]
Shea et al., “S-adenosyl methionine: a natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer's disease,” Alzheimers Disease, 2008; 13(1): pp. 67-70.
[cited by applicant]
Soeken et al., “Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis,” J Fam Pract, 2002; 51(5): pp. 425-443.
[cited by applicant]
Stewart, “Comparison of Intestinal Permeabilities Determined in Multiple in Vitro and in Situ Models: Relationship to Absorption in Humans,” Pharmaceutical Research, 1995; 12(5): pp. 693-699.
[cited by applicant]
Stramentinoli et al., “Pharmacologic aspects of S-adenosylmethionine—Pharmacokinetics and pharmacodynamics,” Am J Med, 1987; 83(5): pp. 35-42.
[cited by applicant]
Stramentinoli, “Adomet as a Drug Pharmacokinetic and Pharmacological Aspects,” Biol Methylation and Drug Design, R.T. Borchardt, New Jersey, Humana Press, 1986: pp. 315-326.
[cited by applicant]
Suchy et al., “Dietary supplementation with S-adenosylmethionine delays the onset of motor neuron pathology in a murine model of amyotrophic lateral sclerosis,” Neuromolecular Med., 2010; 12(1): pp. 86-97.
[cited by applicant]
Szyf, “Epigenetic therapeutics in autoimmune disease,” Clin Rev Allergy Immunol, 2010; 39(1): pp. 62-77.
[cited by applicant]
U.S. Department of Health and Human Services, Office of Dietary Supplements, “Magnesium, Fact Sheet for Health Professionals,” NIH Office of Dietary Supplements, [online], updated Jun. 2022, [retrieved on May 15, 2024].…
[cited by applicant]
Whitehead et al., “Safe and Effective Permeation Enhancers for Oral Drug Delivery,” Pharm. Res., 2008; 25(8): pp. 1783-1788.
[cited by applicant]
Williams et al., “S-adenosylmethionine (SAMe) as treatment for depression: a systematic review,” Clin Invest Med, 2005; 28(3): pp. 132-139.
[cited by applicant]
www.merriam-webster.com/dictionary/food retrieved on Nov. 4, 2011.
[cited by applicant]
Yang et al., “Lupus autoimmunity altered by cellular methylation metabolism,” Autoimmunity, 2013; 46(1): pp. 21-31.
[cited by applicant]
Yang et al., “Pharmacokinetic properties of S-denosylmethionine after oral and intravenous administration of its tosylate disulfate salt: A multiple-dose, open-;label, parallel-group study in healthy Chinese volunteers,…
[cited by applicant]
Ying et al., “Determination and pharmacokinetics of S-adenosylmethionine in human plasma by solid phase extraction-LC/MS,” J China Pharmaceutical University, 2009; 40(1): pp. 67-71 (with English translation).
[cited by applicant]
Yu et al., “Development of short forms from the PROMIS™ sleep disturbance and sleep-related impairment Item Banks,” Behavioral Sleep Medicine, 2012; 10(1): pp. 6-24.
[cited by applicant]
Zhang et al., “Association of magnesium intake with sleep duration and sleep quality: Findings from the Cardia Study,” Sleep, 2021; 45(4): pp. 1-8.
[cited by applicant]
Zhao et al., “Inhibitory effect of S-adenosylmethionine on the growth of human gastric cancer cells in vivo and in vitro,” Chin J Cancer, 2010; 29(8): pp. 752-760.
[cited by applicant]
Algeri et al., “Changes in rat brain noradrenaline and serotonin metabolism after administration of S-Adenosylmethionine,” Biochemical and Pharmacological Roles of Adenosylmethionine and the Central Nervous System, 1979…
[cited by applicant]
Ashton, “Guidelines for the rational use of benzodiazepines. When and what to use,” Drugs, 1994; 48(1): pp. 25-40.
[cited by applicant]
Bottiglieri et al., “S-adenosylmethionine influences monoamine metabolism,” The Lancet, 1984; 324(8396): p. 224.
[cited by applicant]
Bottiglieri, “Folate, vitamin B12, and S-adenosylmethionine,” The Psychiatric clinics of North America, 2013; 36(1): pp. 1-13.
[cited by applicant]
Caro et al., “Antioxidant properties of S-adenosyl-L-methionine in Fe2+-initiated oxidations” Free Radic. Biol. Med., 2004; 36(10): pp. 1303-1316.
[cited by applicant]
Deckert et al., “Adenosinergic psychopharmaceuticals: just an extra cup of coffee?” J of Psychopharmacology, 1990: 183-187.
[cited by applicant]
Deckert et al., “Adenosinergic psychopharmaceuticals?” Trends Pharmacol Sci, 1989;10: pp. 99-100.
[cited by applicant]
Dolan-Sewell et al., “NIH State-of-the-Science Conference on Chronic Insomnia,” Journal of Clinical Sleep Medicine, 2005; 1(4): pp. 335-336.
[cited by applicant]
Dugovic, “Role of serotonin in sleep mechanisms,” Revue neurologique, 2001; 157(11 Pt 2): pp. S16-S19. Abstract only provided.
[cited by applicant]
Fatemeh et al., “Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trials,” Journal of neurology, 2022; 269(1): pp. 205-216.
[cited by applicant]
Filaci et al., “S-adenosil-L-methionine is able to reverse the immunosuppressive effects of chenodeoxycholic acid in vitro”, Int J Immunopharmacol. 1997; 19: pp. 157-165.
[cited by applicant]
Gualano et al., “Anti-inflammatory activity of S-adenosyl-L-methionine: Interference with the eicosanoid system”, Pharmacol. Res. Commun., 1983; 15(7): pp. 683-696.
[cited by applicant]
Hilditch JR et al., “A menopause-specific quality of life questionnaire: development and psychometric properties,” Maturitas, 1996; 24(3): pp. 161-175.
[cited by applicant]
Jo et al., “Polygonatum sibiricum rhizome promotes sleep by regulating non-rapid eye movement and GABAergic/serotonergic receptors in rodent models,” Biomed Pharmacother, 2018; 105: pp. 167-175.
[cited by applicant]
Kajimoto et al., “Hypotensive effect of fermented milk containing gamma-aminobutyric acid (GABA) in subjects with high normal blood pressure,” Journal of the Japanese Society for Food Science and Technology (Japan), 200…
[cited by applicant]
Kravitz et al., “Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition,” Menopause, 2003; 10(1): 19-28.
[cited by applicant]
Matusbara et al., “Effects of GABA supplementation on blood pressure and safety in adults with mild hypertension,” Japanese Pharmacology and Therapeutics, 2002; 30(11): pp. 963-972. Abstract only provided.
[cited by applicant]
Mayo Foundation for Medical Education and Research, “Magnesium supplement (oral route) side effects,” Mayo Clinic, [online], [retrieved Wayback Machine capture of Nov. 9, 2015]. Retrieved from the Internet: <URL: https:…
[cited by applicant]
NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consens State Sci Statements. Jun. 13-15, 2005;22(2):1-30. PMID: 17308547.
[cited by applicant]
Petroff, “GABA and glutamate in the human brain,” The Neuroscientist, 2002; 8(6): pp. 562-573.
[cited by applicant]
Ryba et al., “Z-drugs and Falls: A Focused Review of the Literature,” Sr Care Pharm, 2020; 35(12): pp. 549-554.
[cited by applicant]
Sarris et al., “L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial,” Journal of psychiatric research, 2019; 110, 31-37.
[cited by applicant]
Shaver et al., “Sleep and menopause: a narrative review,” Menopause, 2015; 22(8), 899-915.
[cited by applicant]
Shinitzky et al., “Dynamics of the hydrocarbon layer in liposomes of lecithin and sphingomyelin containing dicetylphosphate,” J. Biol. Chem., 1974; 249(8): pp. 2652-2657.
[cited by applicant]
Shinomiya et al., “Effects of chlorogenic acid and its metabolites on the sleep-wakefulness cycle in rats,” Eur J Pharmacol, 2004; 504: pp. 185-189.
[cited by applicant]
Stramentinoli et al., “Intestinal absorption of S-Adenosyl-L-Methionine,” The Journal of Pharmacology and Experimental Therapeutics, 1979; 209(3): pp. 323-326.
[cited by applicant]
Watanabe et al., “GABA and GABA receptors in the central nervous system and other organs,” International Review of Cytology, 2002; 213: pp. 1-47.
[cited by applicant]
Wu et al., “Synthesis of gallic acid esters and their antibloodplatelet aggregation,” Fine Chemical, 1998; 15(4): pp. 9-12.
[cited by applicant]
Yokogoshi et al., “Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats,” Neurochem Res, 1998; 23(5): pp. 667-673.
[cited by applicant]
Yuhua et al., “Study on the Synthesis and Application of Cottonseed Oil Diethanolamide,” Fine Chemicals, 1998; 15(4): pp. 6-9. Retrieved from the Internet: <URL: https://www.alljournals.cn/view_abstract.aspx?pcid=5B3AB9…
[cited by applicant]
PCT/US2024/029467 International Search Report and Written Opinion mailed Nov. 20, 2024.
[cited by applicant]